Home > Insider Trading > Filing (0001209191-20-017538)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1438533	Retrophin Inc.	RTRX	Pharmaceutical Preparations (2834)	262383102

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1579649	L. Noah Rosenberg	C/O Retrophin, Inc. 3721 Valley Centre Drive, Suite 200 San Diego CA 92130	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-05	5,000	$0.00	29,045	No	4	A	Direct
Common Stock	Disposition	2020-03-05	1,790	$15.36	27,255	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Footnotes

On July 26, 2018, the reporting person was granted performance restricted stock units (PRSUs) covering 10,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On March 5, 2020, a portion of the PRSUs vested upon the Issuer's confirmation that the first 190 patients in the sparsentan DUPLEX Phase 3 Study had been enrolled
Includes an aggregate of 1,545 shares of the Issuer's common stock acquired by the reporting person on May 31, 2019 and November 30, 2019 pursuant to an employee stock purchase program.
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.